Wild-type mice were subjected to the MMP model and received 1, 5, or 10 mg/kg body weight CP-105,696 or its vehicle daily p.o. starting on day 0. (A) Progression of skin inflammation assessed by the percentage of the total body surface affected by skin lesions (n = 7–8 male and 8 female mice/group). (B) Representative pictures of all groups on day 13. Arrows indicate inflammatory lesions. (C) Comparison of the severity of mucosal lesions in the oropharynx evaluated by the endoscopy score (n = 7–8 male and 8 female mice/group). (D) Representative endoscopy pictures of mucosal surfaces on day 16. Arrows indicate inflammatory lesions. (E) Contingency table of the number of vehicle- and 10 mg/kg CP-105,696–treated mice with and without conjunctival lesions (7 male and 7 female mice/group). The frequency of mice with inflammatory lesions statistically significantly differed between the 2 groups with P < 0.01 determined by χ² test. (F) Representative H&E staining of the conjunctiva of vehicle- and CP-105,696–treated mice on day 16. Scale bars equal 50 μm. All results are presented as mean ± SEM. In C, each dot represents a mouse. The results were examined for statistical significance in A by 2-way ANOVA and Holm-Šídák post hoc test and in C by Kruskal-Wallis test with Dunn’s correction for multiple comparisons. In A, at the days indicated, *P < 0.05; **P < 0.01; ****P < 0.0001 for the comparison of the indicated groups with the vehicle group; ^#P < 0.05; ^##P < 0.01; ^###P < 0.001 for the comparison of the indicated group with the 10 mg/kg CP-105,696 treatment group. In C, *P < 0.05; **P < 0.01 for the comparisons indicated.